Shots:

• The EC has granted approval to Vyloy + fluoropyrimidine & Pt-based CT as a 1L treatment of CLDN 18.2+, HER2-ve, locally advanced unresectable or metastatic G/GEJ adenocarcinoma in adults with tumors, valid across the EU plus Iceland, Liechtenstein & Norway
• The approval was based on the P-III (SPOTLIGHT & GLOW) studies assessing Vyloy + mFOLFOX6 and Vyloy + CAPOX, respectively, vs PBO as a 1L treatment of CLDN 18.2+, HER2-ve, locally advanced unresectable or metastatic G/GEJ cancer
• Studies showed improved PFS, with mPFS of 10.61mos. vs 8.67mos. (SPOTLIGHT) & 8.21mos. vs 6.80mos. (GLOW) as well as improved OS, with mOS of 18.23mos. vs 15.54mos. (SPOTLIGHT) & 14.39mos. vs 12.16mos. (GLOW)

Ref: Astellas | Image: Astellas

Related News:- Astellas Reports the US FDA Listing of DIGITIVA to Manage Heart Failure

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com